Filtern
Volltext vorhanden
- ja (291)
Gehört zur Bibliographie
- ja (291)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (291) (entfernen)
Schlagworte
- Toxikologie (119)
- DNA damage (15)
- Adenosine receptors (9)
- Adenosinrezeptor (8)
- oxidative stress (7)
- DNS-Schädigung (6)
- GPCR (6)
- Genotoxicity (6)
- DNA (5)
- DNA binding (5)
- G-Protein gekoppelte Rezeptoren (5)
- Micronuclei (5)
- Pharmakologie (5)
- Adenylate cyclase (4)
- FRET (4)
- Fluoreszenz-Resonanz-Energie-Transfer (4)
- G proteins (4)
- Medizin (4)
- Oxidativer Stress (4)
- micronuclei (4)
- mycotoxin (4)
- 1 (3)
- Biotransformation (3)
- Carcinogen (3)
- Carcinogenesis (3)
- Carcinogenicity (3)
- Carcinogens (3)
- DNA-Schaden (3)
- ERK1/2 (3)
- Enzyme induction (3)
- Ernährung (3)
- G protein-coupled receptors (3)
- Pneumolysin (3)
- apoptosis (3)
- cAMP (3)
- cytoskeleton (3)
- genotoxicity (3)
- heart failure (3)
- inflammation (3)
- liver (3)
- metabolism (3)
- nephrotoxicity (3)
- signal transduction (3)
- transcription factors (3)
- 18F-FDG (2)
- 5-Azacytidine (2)
- A1 adenosine receptors (2)
- Adenosin (2)
- Adrenerger Rezeptor (2)
- Aldosteron (2)
- Ames test (2)
- Angiotensin II (2)
- Bakteriengift (2)
- Benzene (2)
- Carcinogenität (2)
- DNA Binding (2)
- DNA Schaden (2)
- DNA repair (2)
- Diethylstilbestrol (2)
- Dose response (2)
- Dose-response relationship (2)
- Electropermeabilization (2)
- Estrogen (2)
- FCS (2)
- Förster Resonanz Energie Transfer (2)
- G-Protein gekoppelter Rezeptor (2)
- G-protein (2)
- Genotoxizität (2)
- HPLC-MS (2)
- Herzhypertrophie (2)
- Hirnhautentzündung (2)
- Hormone (2)
- In vitro (2)
- Inhalation (2)
- Insulin (2)
- Kleinkern (2)
- Leber (2)
- Meningitis (2)
- Micronucleus (2)
- Muscarinrezeptor (2)
- Mutagenität (2)
- Myokarditis (2)
- N-formyl peptides (2)
- Niere (2)
- PET (2)
- Pharmakokinetik (2)
- Pharmazie (2)
- QIVIVE (2)
- RKIP (2)
- Radioligand binding (2)
- Rat (2)
- Reproductive toxicity (2)
- Risk Assessment (2)
- Salmonella/microsome assay (2)
- Silicones (2)
- Toxicology (2)
- Toxin (2)
- actin (2)
- actinomycetes (2)
- adenosine receptors (2)
- aldosterone (2)
- barbiturates (2)
- biased signaling (2)
- binding (2)
- biomedicine, general (2)
- cGMP (2)
- calcium (2)
- cancer risk (2)
- carcinogen (2)
- carcinogenicity (2)
- cardiac hypertrophy (2)
- cell biology (2)
- comet assay (2)
- cytokinins (2)
- dialysis (2)
- differentiation (2)
- environmental health (2)
- familial DCM (2)
- fluorescence (2)
- fluorescence resonance energy transfer (2)
- genomic damage (2)
- heart (2)
- immunohistochemistry (2)
- in-vivo (2)
- insulin (2)
- kidneys (2)
- lymphocytes (2)
- mast cells (2)
- medicine (2)
- membrane skeleton (2)
- meningitis (2)
- mercapturic acid (2)
- mutagenicity (2)
- myocarditis (2)
- occupational medicine/industrial medicine (2)
- pharmacogenetics (2)
- pharmacokinetics (2)
- pharmacology/toxicology (2)
- pneumolysin (2)
- positron emission tomography (2)
- rat brain membranes (2)
- receptors (2)
- resveratrol (2)
- risk assessment (2)
- therapy (2)
- toxicity (2)
- uremic toxins (2)
- vitamin B6 (2)
- yam (2)
- (Mouse L-cell) (1)
- (Rat brain membrane) (1)
- (Rat liver) (1)
- (Salmonella) (1)
- 1H-NMR-Spectroscopy (1)
- 2 (1)
- 2',7'-dichlorofluorescin (1)
- 2-Acetylaminofluorene (1)
- 2-Dichloroethane (1)
- 2-Dioxetane (1)
- 2-Generation reproduction (1)
- 2-acetylaminofluorene (1)
- 3 (1)
- 3-pentafluoropropene (1)
- 3-tetrafluoropropene (1)
- 3R (1)
- 4'-hydroxylation (1)
- 4-(p-nitrobenzyl)pyridine (1)
- 6-benzylaminopurine (1)
- 7,8-dihydroxyflavone (7,8-DHF) (1)
- 8-Hydroxy-deoxyguanosine (1)
- A(2B) receptors (1)
- A1 (1)
- A1 Adenosine receptors (1)
- A2B adenosine receptor (1)
- A2BAR (1)
- A<sub>2</sub> Adenosine receptor (1)
- AMPK (1)
- API-Massenspektrometrie (1)
- AUM (1)
- A\(_{2A}\) adenosine receptor antagonist (1)
- Acetylcysteinderivate (1)
- Acrylamid (1)
- Acrylamide (1)
- Actin (1)
- Actin cytoskeleton (1)
- Adenosine receptor (1)
- Adenosine receptor antagonists (1)
- Adrenergic receptor (1)
- Adverse outcome pathway (AOP) (1)
- Aflatoxin (1)
- Aflatoxin B1 (1)
- Aldosteronantagonist (1)
- Alkylation (1)
- Alzheimers disease (1)
- Amino acid composition (1)
- Amino acids (1)
- Aminosäuren (1)
- Anabolieagent (1)
- Angiotensin-II-Blocker (1)
- Angst (1)
- Aniline derivatives (1)
- Animal model (1)
- Anthocyane (1)
- Anthraquinone glycosides (1)
- Antibodies (1)
- Antikörper (1)
- Anxiety (1)
- Apoptose (1)
- Apoptosis (1)
- Aryl hydrocarbon rnonooxygenase (1)
- Astrozyt (1)
- Atria (1)
- Aufmerksamkeits-Defizit-Syndrom (1)
- Autofocus (1)
- Azole (1)
- Azoles (1)
- B cells (1)
- BETA(2)-adrenergic receptor (1)
- BRET (1)
- Background DNA damage (1)
- Bacterial Toxins (1)
- Bacterial meningitis (1)
- Bakterielle Hirnhautentzündung (1)
- Bakterien (1)
- Barbiturat (1)
- Barbiturates (1)
- Barth syndrome (1)
- Bcl-2 (1)
- Benfotiamin (1)
- Benzefuran dioxetane (1)
- Benzefuran epoxide (1)
- Benzo(a)pyrene-DNA binding (1)
- Berenil (1)
- Beta(1)-adrenergic receptor (1)
- Beta(2)-adrenergic receptor (1)
- Beta-1-Rezeptor (1)
- Beta-1-receptor (1)
- Beta-Adrenergic Receptor (1)
- Beta-Adrenozeptor (1)
- Bioluminescence resonance energy transfer (1)
- Biomarker (1)
- Biomarkers (1)
- Biosensor (1)
- Bisphenol A (1)
- Bromodeoxyuridine labeling (1)
- Brustkrebs (1)
- C1q/TNF related protein (CTRP) (1)
- CAMP production (1)
- CFC replacements (1)
- CIB1 (1)
- CRISPR/Cas9 (1)
- CXCR4 (1)
- CYP19 (1)
- CYP51 (1)
- CaMKII (1)
- Calcium (1)
- Cancer prevention (1)
- Carcinogen risk Individual susceptibili (1)
- Carcinogenic potency (1)
- Cardiac myocyte ; Beta-Receptor ; Muscarinic receptor ; cAMP ; G-protein ; Serum (1)
- Cardiomyocyte (1)
- Cell adhesion (1)
- Cell death and comet assay (1)
- Cell transformation (1)
- Chemical carcinogenesis (1)
- Chemokine (1)
- Chemokine receptors (1)
- Chemotactic receptors (1)
- Chlorfluorkohlenstoffe (1)
- Choline deficiency (1)
- Cholinesteraseinhibitor (1)
- Chromosome aberration (1)
- Chromosome distribution (1)
- Chronic heart-failure (1)
- Clonidin (1)
- Colon cancer (1)
- Comet Assay (1)
- Comet assay (1)
- Covalent DNA binding (1)
- Covalent binding (1)
- Covalent binding index (1)
- Covalent binding index - Diethylstilbestrol (1)
- Cyclic AMP (1)
- Cyclo-AMP (1)
- Cyclo-GMP (1)
- Cytochrom P450 (1)
- Cytochrome b5 (1)
- Cytologie (1)
- DAMGO (1)
- DCM genetic background (1)
- DES (1)
- DNA Damage (1)
- DNA adduct . Repair endonuclease (1)
- DNA adducts (1)
- DNA binching (1)
- DNA damage response (1)
- DNA metabolism (1)
- DNA methylation (1)
- DNA transfection (1)
- DNA-Addukte (1)
- DNS-Bindung (1)
- DNS-Strangbruch (1)
- Depression (1)
- Dermatologie (1)
- Di (1)
- Dietary process-related contaminants (1)
- Diisononyl phthalate (1)
- Dilated cardiomyopathy (1)
- Dioscorea (1)
- Dose response relationships (1)
- Dosis-Wirkungs-Beziehung (1)
- Drug resistance (1)
- Dualstere Liganden (1)
- Dualsteric Ligands (1)
- ERK signaling (1)
- ERK-Kaskade (1)
- ERK-cascade (1)
- Electric Field (1)
- Electrical breakdown (1)
- Electrophiles (1)
- Elektrofusion (1)
- Elektroporation (1)
- Emodin (1)
- Endogenous genotoxicity (1)
- Entzündung (1)
- Epoxide hydrolase (1)
- Erk1/2 (1)
- Ersatzstoff (1)
- Estrone (1)
- Ethionine (1)
- Eukaryotic cell (1)
- Excitotoxicity (1)
- External exposure assessment (1)
- Extrakorporale Dialyse (1)
- FCKW-Ersatzstoffe (1)
- FPG protein (1)
- FRET sensors (1)
- Fabry Disease (FD) (1)
- Fischer 344 rats (1)
- Flow cytometry (1)
- Fluorescence (1)
- Fluorescence Correlation Spectroscopy (1)
- Fluorescence Microscopy (1)
- Fluorescence resonance energy transfer (1)
- Fluorescence-resonance-energy-transfer (1)
- Fluoreszenz (1)
- Fluoreszenzkorrelationsspektroskopie (1)
- Fluoreszenzmikroskopie (1)
- Fluorkohlenwasserstoffe (1)
- Fluoxetin (1)
- Fluoxetine (1)
- Friedreich’s ataxia (1)
- Fumonisin B1 (1)
- Fumonisine (1)
- Fungizid (1)
- Furan (1)
- Förster Resonance Energy Transfer (1)
- G Protein-Coupled Receptor (1)
- G protein coupled receptor (1)
- G protein coupled receptor (GPCR) (1)
- G protein-coupled receptor (1)
- G protein-coupled receptor kinase (1)
- G-protein coupled receptor (1)
- G-protein-coupled receptors (1)
- GABA-receptor complex (1)
- GC-MS (1)
- GC/MS (1)
- GPCR dimerisation (1)
- GPCR signaling (1)
- GPCRs (1)
- GTP-bindende Proteine (1)
- Gastric carcinogenesis (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- Gene Transfer (1)
- Gene transfer (1)
- Genetic instability (1)
- Genomschaden (1)
- Genotyp (1)
- Gentoxikologie (1)
- Glutathion S-Konjugat (1)
- Glutathione Stransferase (1)
- Guanin Nukleotid Austauschfaktor (1)
- Guaninnucleotid-Austauschfaktoren (1)
- Guanylatcyclase (1)
- HCN channel (1)
- HCN-Kanal (1)
- HFC245fa (1)
- HIV (1)
- HIV infection (1)
- HPLC-MS/MS method (1)
- HeLa cells (1)
- Heart failure (1)
- Hemmung der Proliferation schnell wachsender Krebszellen (1)
- Herpesviren (1)
- High-thropughput screening (1)
- High-throughput screening (1)
- Hintergrund-DNA-Schaden (1)
- Hochdurchsatz-Screening (1)
- Hoechst 33258 dye (1)
- Homocystein (1)
- Hsp90 (1)
- Human platelets (1)
- Hybridoma (1)
- Häm (1)
- I1 Imidazolin Bindungsstelle (1)
- I1 imidazoline binding site (1)
- Immunization (1)
- Immunologie (1)
- In vitro testing (1)
- In vitro toxicity testing (1)
- In vivo (1)
- In-silico Modell (1)
- Inflammation (1)
- Inhibition (1)
- Ischemia/reperfusion (1)
- K + -channels (1)
- Kanzerogenese (1)
- Kardiomyozyt (1)
- Kidneys (1)
- Kinetochore (1)
- Kinetochores (1)
- Knockout (1)
- Kongestive Herzmuskelkrankheit (1)
- Krebs (1)
- Krebs <Medizin> (1)
- L5178Y cells (1)
- LC-MS (1)
- LC-MS/MS (1)
- LTB4 receptor (1)
- Latrophilin (1)
- Leukocyte/endothelium interaction (1)
- Ligand <Biochemie> (1)
- Lung (1)
- MAP-Kinase (1)
- MMQ cells (1)
- Magenkrebs (1)
- MammaJian mutagenicity test (1)
- Massenspektrometrie (1)
- Mastzelle (1)
- Maus (1)
- Mechanism of action (1)
- Melanocortin 4 receptor (MC4R) (1)
- Melanocyte stimulating hormones MSH (1)
- Merkaptolaktat (1)
- Merkaptursäure (1)
- Merkaptursäuren (1)
- Metabolic activation (1)
- Metabolism (1)
- Metabolism saturation (1)
- Metabolismus (1)
- Metabonomics (1)
- Metabonomix (1)
- Methylphenidat (1)
- Microcirculation (1)
- Micronucleus formation (1)
- Micronucleus test (1)
- Microscopy (1)
- Mikrokerne (1)
- Mitosis (1)
- Molekularpharmakologie (1)
- Multivariate Analyse (1)
- Mutagenicity (1)
- Mutagenicity assay (1)
- Mutagenitätstest (1)
- Mutagens (1)
- Mutation assay (1)
- Mykotoxin (1)
- N-methyl-N-nitrosourea (1)
- N1E 115 cells (1)
- NADPH-Oxidase (1)
- Neomycin Resistance (1)
- Nephrotoxicity (1)
- Nephrotoxizität (1)
- Nervennetz (1)
- Nervenzelle (1)
- Nitrosation (1)
- Nitrosativer Stress (1)
- Nitrosierung (1)
- OXPHOS (1)
- Oxidative Stress (1)
- Oxidative stress (1)
- Oxygen radical (1)
- PBPK/PBTK model (1)
- PDE (1)
- PDE2 (1)
- PDXP inhibitors (1)
- PKA (1)
- PTH1R (1)
- Parathormon (1)
- Partial Agonists (1)
- Partialagonismus (1)
- Patulin (1)
- Peptides (1)
- Perforine (1)
- PhD thesis pharmacology (1)
- Pharmakogenetik (1)
- Phosphatase (1)
- Phosphatasen (1)
- Phosphodiesterase (1)
- Phosphoglykolat-Phosphatase (1)
- Phosphoglykolatphosphatase (1)
- Photoaffinity labelling (1)
- Physiologically based kinetic models (1)
- Physiologie (1)
- Phänotyp (1)
- Pointmutation (1)
- Pore (1)
- Pore formation (1)
- Pore-formation (1)
- Porenbildung (1)
- Prevalence (1)
- Prognostic impact (1)
- Prolactin (1)
- Propenderivate (1)
- Protein binding (1)
- Protein coding (1)
- Proteinaddukte (1)
- Proteinbindung (1)
- Proteintyrosinphosphatase (1)
- Protonen-NMR-Spektroskopie (1)
- Quantitative risk assessment (1)
- RAMP (1)
- RBM20 mutations (1)
- ROS (1)
- Radiation inactivation (1)
- Radicals (1)
- Radioligand binding - 86Rb + -efflux (1)
- Radioligands (1)
- Radioligauds (1)
- Raf kinase inhibitor protein (1)
- Raman micro-spectroscopy (1)
- Rat Iiver microsomes (1)
- Rat liver peroxisome (1)
- Ratte (1)
- Reactive intermediates (1)
- Reaktive Zwischenstufe (1)
- Receptor (1)
- Receptor dynamics (1)
- Regulation (1)
- Regulator of G protein signaling 2 (1)
- Renin-Angiotensin-System (1)
- Resveratrol (1)
- Rgs2 (1)
- Riot control agents (1)
- Risikoanalyse (1)
- Risikobewertung (1)
- Risk assessment (1)
- Risk estimation (1)
- Risk-factors (1)
- SCN5a (1)
- ST-elevation myocardial infarction (1)
- Salmonella typhimurium (1)
- Sensitivity (1)
- Sensor (1)
- Short-term tests (1)
- Signal transduction (1)
- Species Differences (1)
- Species differences (1)
- Spermatogenesis (1)
- Speziesunterschiede (1)
- Spontaneous tumours (1)
- Src (1)
- Stable Transformation (1)
- Statin (1)
- Stickstoffoxidsynthase (1)
- Streptococcus pneumoniae (1)
- Streptomyces (1)
- Stress (1)
- Structureactivity relationship (1)
- Styrol (1)
- Systembiologie (1)
- T cells (1)
- TK6 cells (1)
- Target size (1)
- Theophylline (1)
- Thymidine glycol (1)
- Tiermodell (1)
- Toxicokinetics (1)
- Toxikokinetik (1)
- Toxizität (1)
- Toxizitätstest (1)
- Transfection (1)
- Transgenic mouse (1)
- Transgenie mice (1)
- Transkriptionsfaktoren (1)
- Trenbolone (1)
- Trifluorpropionsäure (1)
- Tumorzelle (1)
- Tyrosin (1)
- Tyrosin phosphatase (1)
- Unscheduled DNA synthesis (1)
- Urämische Toxine (1)
- Uterine tumors (1)
- Valvular heart-desease (1)
- Venerologie (1)
- Volume distribution (1)
- Wachstumskonus (1)
- Water resources (1)
- Xanthines (1)
- Zell-Adhäsion (1)
- Zelladhäsion (1)
- Zelle (1)
- Zellkultur (1)
- Zellskelett (1)
- Zellteilung (1)
- Zelltransport (1)
- [3H]PIA binding (1)
- absorption (1)
- activation (1)
- active zone (1)
- acute slices (1)
- adduct (1)
- adenine (1)
- adenosine (1)
- adenosine 3',5'-cyclic monophosphate (1)
- adenylate cyclase (1)
- adenylyl cyclase signaling cascade (1)
- adenylyl-cyclase isoforms (1)
- adhesion GPCR (1)
- adiponectin (1)
- adipose tissue (1)
- adrenerge Rezeptoren (1)
- adrenergic receptors (1)
- adult cardiac myocytes (1)
- adverse outcome pathway (1)
- adverse outcome pathway (AOP) (1)
- aflatoxin (1)
- aflatoxin B1 (1)
- ageing (1)
- agonists (1)
- alkylation (1)
- allelic variant (1)
- alpha2-KO Maus (1)
- alpha2-KO mouse (1)
- alpha2-Rezeptor (1)
- alpha2-receptor (1)
- alternative methods (1)
- amine (1)
- amino acid (1)
- antagonists (1)
- anthocyanins (1)
- anti-Parkinson agents (1)
- anti-inflammatory agents (1)
- antibacterial/antiviral drug (1)
- antibodies (1)
- antibody/autoantibody (1)
- antioxidants (1)
- aortocaval fistula model (1)
- aromatic amides (1)
- arrhythmia (1)
- arrhythmogenesis (1)
- assay (1)
- association (1)
- astrocytes (1)
- atopic eczema (1)
- atrial natriuretic peptide (1)
- avaliação de risco (1)
- bacterial meningitis (1)
- bariatric surgery (1)
- base excision repair (incision activity) (1)
- beta2-adrenoceptor knockout (1)
- beta3 CL 316,243 (1)
- binding affinity (1)
- bioactive compounds (1)
- biofilms (1)
- biology (1)
- biomarker (1)
- biomarker of exposure (1)
- biomarkers (1)
- biotransformation (1)
- bisphenol a (1)
- blood coagulation factor XIII (1)
- blood plasma (1)
- blood pressure (1)
- blood samples (1)
- bone marrow (1)
- brain damage (1)
- brain membranes (1)
- calcitonin gene-related peptide (1)
- calmodulin (1)
- cancer (1)
- cardiac magnetic resonance imaging (1)
- cardiac myocyte ; muscarinic K current ; G-protein ; Albumin ; serum (1)
- cardiac remodelling (1)
- cardiomyocyte (1)
- cardiomyocytes (1)
- cardiovascular diseases (1)
- caveolin-1 (1)
- cell adhesion (1)
- cell culture (1)
- cell fate (1)
- cell fusion (1)
- cell proliferation (1)
- cell staining (1)
- cellular-trafficking (1)
- chalcone (1)
- chemotactic receptors (1)
- chemotaxis (1)
- child health (1)
- cholesterol depletion (1)
- cholesterol-dependent cytolysin (1)
- cholinesterase (1)
- cholinesterase inhibitors (1)
- chronic heart failure (1)
- chronic kidney disease (1)
- chronophin (1)
- cisplatin (1)
- classification (1)
- classification and labeling (1)
- clonidine (1)
- co-culture (1)
- coated vesicles (1)
- cognitive impairment (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- compartments (1)
- conduction disease (1)
- conformational auto-epitope (1)
- conjugated mycotoxins (1)
- constitutive activity (1)
- contact lens (1)
- continuous (1)
- contractility (1)
- coumarin (1)
- coupled (1)
- coupled receptor (1)
- covalent (1)
- covalent binding (1)
- creatinine (1)
- crystal structure (1)
- cyclic AMP (1)
- cyclic dipeptide (1)
- cyclic nucleotides such as cyclic adenosine monophosphate (1)
- cyclic peptides/cyclopeptides (1)
- cyclic-AMP (1)
- cyclic-gmp (1)
- cyclopeptide therapy (1)
- cytochrome P450 2C9 (1)
- cytochrome P450s (1)
- cytochrome p450 (1)
- cytogenetic effects (1)
- cytome biomarkers (1)
- cytosol (1)
- cytotoxic (1)
- dCIRL (1)
- danio rerio (1)
- definition (1)
- dendritic spines (1)
- desensitization (1)
- detrusor muscle (1)
- developmental biology (1)
- diabetes (1)
- diagnosis (1)
- dicyclohexyl phthalate (1)
- diet (1)
- dilated cardiomyopathy with ataxia (1)
- disrupting chemicals (1)
- disruptor endócrino (1)
- docking (1)
- domains (1)
- dormancy (1)
- dose (1)
- down-regulation (1)
- drug (1)
- dualsteric ligands (1)
- dunce (1)
- eccentric hypertrophy (1)
- ectodomain cleavage (1)
- efficient intervention points (1)
- endocrine disruptor (1)
- endogenous (1)
- energy-transfer (1)
- environmental phenols (1)
- enzyme-linked immunoassays (1)
- estrogen receptor (1)
- ethanol (1)
- etoposide (1)
- etox database (1)
- eugenol (1)
- exposição humana (1)
- exposure (1)
- extrapolation (1)
- fatty liver (1)
- fentanyl (1)
- fetal testis (1)
- fluorescence correlation spectroscopy (1)
- fluorescence detection (1)
- fluorescence imaging (1)
- fluorescence recovery after photobleaching (1)
- fluorescent probes (1)
- fluorocarbons (1)
- food contact materials (1)
- food safety (1)
- food security (1)
- formyl peptides (1)
- fumonisin B1 (1)
- functional clustering (1)
- fungi (1)
- furan (1)
- gastrointestinal cancer (1)
- general medicine (1)
- genetics (1)
- genotoxic (1)
- genotypes (1)
- genotyping (1)
- glucuronide (1)
- glutamate (1)
- glutathion S-conjugate (1)
- glycolytic flux control (1)
- gprotein (1)
- gravidez (1)
- growth cone (1)
- guanine nucleotide exchange factor (1)
- hA<sub>3</sub>AR (1)
- hOCT1 (1)
- haematopoietic stem cells (1)
- halo olefines (1)
- haloacid dehalogenase (1)
- healing and remodelling processes (1)
- heme (1)
- heterogeneous population (1)
- hiPSC-CM (1)
- hidden mycotoxins (1)
- histamine release (1)
- homeostasis (1)
- homocysteine (1)
- homodimerization (1)
- hormone receptors (1)
- human (1)
- human A(3) (1)
- human biomonitoring (1)
- human exposure (1)
- human lung (1)
- hydrofluorocarbons (1)
- hypertension (1)
- hypertonic solution (1)
- iPSC-cardiomyocytes (1)
- identification (1)
- impact pharmacogenetics (1)
- in vitro (1)
- in vivo (1)
- in-silico model (1)
- individual (1)
- indolylpyrimidylpiperazines (1)
- induced pluripotent stem cell cardiomyocytes (1)
- induced pluripotent stem cells (1)
- induzierte Phosphatasen MKP-1 und MKP-2 (1)
- inflammatory diseases (1)
- inhalation (1)
- inhibitors (1)
- insulin signaling (1)
- internalization (1)
- international union (1)
- intracellular calcium release (1)
- intracellular loop (1)
- intrinsic metabolism (1)
- ionic look (1)
- ischemic stroke (1)
- isoproterenol (1)
- key event relationship (1)
- kidney (1)
- kinases (1)
- laminopathy (1)
- lamivudine (1)
- legislation (1)
- life (1)
- ligand binding (1)
- lipid rafts (1)
- lipidomics (1)
- listeriolysin O (1)
- live imaging (1)
- liver microsomes (1)
- living vells (1)
- long-read sequencing (1)
- lovastatin (1)
- lysosomal disruption (1)
- lysosomal storage disorders (1)
- lösliche Guanylylcyclase (1)
- mTOR-inhibitor RAD-001 (1)
- maintenance of genomic integrity (1)
- male rats (1)
- mammalian genomics (1)
- marine sponges (1)
- masked mycotoxins (1)
- mass spectrometry (1)
- matrix metalloproteinase (1)
- maturation strategies (1)
- mechanotransduction (1)
- membrane (1)
- membrane transporters (1)
- memory B cells (1)
- mercaptolactic acid (1)
- mercapturic acids (1)
- metabolites (1)
- metabonomics (1)
- metabotropic signalling (1)
- micronucleus assay (1)
- micronucleus test (1)
- microvessel permeability (1)
- mild (1)
- mitochondria (1)
- mitochondrial DNA polymerase γ (1)
- mitochondrial cardiomyopathy (1)
- mitotic disturbance (1)
- modelo PBPK/PBTK (1)
- modified mycotoxins (1)
- molecular biology (1)
- molecular dynamics (1)
- molecular modeling (1)
- molecular modelling (1)
- monogenetic cardiomyopathies (1)
- mortality (1)
- mouse lymphoma L5178Y (1)
- mouse models DNA damage (1)
- mucosa (1)
- multivariate analysis (1)
- multivariate data analysis (1)
- muscarinic acetylcholine receptor (1)
- mutagen (1)
- mutant mice (1)
- mutation triggers (1)
- mycotoxin derivates (1)
- mycotoxin metabolites (1)
- mycotoxins (1)
- n-hexyl phthalate (1)
- nanopore (1)
- natural (1)
- neocortex (1)
- neurodegenerative diseases (1)
- neuronal dendrites (1)
- neurons (1)
- neutrophils (1)
- nitric-oxide (1)
- nitrosation (1)
- nitrosative stress (1)
- nitroso compound (1)
- no (1)
- nutritional composition (1)
- o-Chlorobenzylidene malononitrile (1)
- obesity (1)
- occurrence (1)
- ochratoxin A (1)
- octopamine (1)
- oligomerization (1)
- opioid ligands (1)
- opioid receptor (1)
- optimal drug combination (1)
- optimal drug targeting (1)
- optimal pharmacological modulation (1)
- optimal treatment strategies (1)
- organ toxicity (1)
- oxidativer Stress (1)
- p53 (1)
- parathyroid hormone (1)
- parathyroid hormone 1 receptor (1)
- partial agonists (1)
- performance liquid-chromatography (1)
- peripheral nerve (1)
- peripheral-blood lymphocytes (1)
- personalized treatment (1)
- perspectives (1)
- pharmacology (1)
- phenotyping (1)
- phosphoglycolate phosphatase (1)
- phosphoinositides (1)
- phosphorylation (1)
- photoaffinity labelling (1)
- plasma membrane (1)
- poly(ADP-ribosyl)ation (1)
- pore formation (1)
- pore-forming toxin (1)
- potent (1)
- pregnancy (1)
- primary aromatic amine (1)
- protein (1)
- protein adducts (1)
- protein alkylation (1)
- protein design (1)
- protein-coupled receptors (1)
- protein-coupled-receptors (1)
- psoriasis (1)
- purine derivatives (1)
- pyridoxal phosphatase (1)
- pyridoxal phosphatase (PDXP) (1)
- pyrrolizidine alkaloids (1)
- quantitative assessments (1)
- radiation (1)
- radii (1)
- radioligand (1)
- radioligand binding (1)
- rat pheochromocytoma cells (1)
- rats (1)
- reactive metabolites (1)
- reaktive Metabolite (1)
- receptor binding (1)
- receptor pharmacology (1)
- receptor solubilization (1)
- receptor-G protein coupling (1)
- receptor-G protein coupling. (1)
- reduction of ERK1/2 phosphorylation (1)
- reduction of cells proliferation (1)
- regulation (1)
- relaxation (1)
- renal toxicity (1)
- repeated dose (1)
- reproductive and developmental toxicity (1)
- risk (1)
- risk-assesment (1)
- sensor (1)
- sensory physiology (1)
- serum (1)
- sex (1)
- sexual development (1)
- signaling microdomain (1)
- simulated digestion (1)
- single-molecule imaging (1)
- single-molecule microscopy (1)
- solid-phase extraction (1)
- solubilization (1)
- soluble guanylyl cyclase (1)
- sponges (1)
- spontaneously hypersensitive-rats (1)
- staphilococci (1)
- statins (1)
- stomach (1)
- streptomyces (1)
- sub-Saharan Africa (1)
- subtypes (1)
- sugars (1)
- susceptibility (1)
- synapses (1)
- synaptic plasticity (1)
- tMCAO (1)
- tandem mass-spectrometry (1)
- targets (1)
- testosterone production (1)
- tetrafluoropropene (1)
- therapeutic potential (1)
- thyroid hormone (1)
- tissue (1)
- tolbutamide substrate (1)
- toxicity testing (1)
- toxicocinética (1)
- toxicokinetics (1)
- toxicology (1)
- trans-1 (1)
- trans-Golgi network (1)
- transgenic animals (1)
- triazolotriazine derivatives (1)
- trifluoropropionic acid (1)
- tuber (1)
- tumour (1)
- tyrosine phosphatase (1)
- ultrastructure (1)
- urea (1)
- variocosities (1)
- vav2 (1)
- vitamin-D-receptor (1)
- volume overload (1)
- warfarin polymorphisms (1)
- weight of evidence (1)
- yellow fluorescent protein (1)
- µ-Opioid receptor (1)
- β-adrenergic receptors (1)
- β1-adrenoceptor/β1-adrenergic receptor (1)
- βAR (1)
Institut
- Institut für Pharmakologie und Toxikologie (291) (entfernen)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (1)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (1)
- Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V. (1)
- Max Delbrück Center for Molecular Medicine (1)
- Max-Delbrück-Center für molekulare Medizin, Berlin (1)
- Pharmakologie, Universität Bonn (1)
- Pharmazie, Universität Mailand (1)
RBM20 mutations account for 3 % of genetic cardiomypathies and manifest with high penetrance and arrhythmogenic effects. Numerous mutations in the conserved RS domain have been described as causing dilated cardiomyopathy (DCM), whereas a particular mutation (p.R634L) drives development of a different cardiac phenotype: left-ventricular non-compaction cardiomyopathy. We generated a mutation-induced pluripotent stem cell (iPSC) line in which the RBM20-LVNC mutation p.R634L was introduced into a DCM patient line with rescued RBM20-p.R634W mutation. These DCM-634L-iPSC can be differentiated into functional cardiomyocytes to test whether this RBM20 mutation induces development of the LVNC phenotype within the genetic context of a DCM patient.
Highlights
• Loss of DNAJC19's DnaJ domain disrupts cardiac mitochondrial structure, leading to abnormal cristae formation in iPSC-CMs.
• Impaired mitochondrial structures lead to an increased mitochondrial respiration, ROS and an elevated membrane potential.
• Mutant iPSC-CMs show sarcomere dysfunction and a trend to more arrhythmias, resembling DCMA-associated cardiomyopathy.
Background
Dilated cardiomyopathy with ataxia (DCMA) is an autosomal recessive disorder arising from truncating mutations in DNAJC19, which encodes an inner mitochondrial membrane protein. Clinical features include an early onset, often life-threatening, cardiomyopathy associated with other metabolic features. Here, we aim to understand the metabolic and pathophysiological mechanisms of mutant DNAJC19 for the development of cardiomyopathy.
Methods
We generated induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) of two affected siblings with DCMA and a gene-edited truncation variant (tv) of DNAJC19 which all lack the conserved DnaJ interaction domain. The mutant iPSC-CMs and their respective control cells were subjected to various analyses, including assessments of morphology, metabolic function, and physiological consequences such as Ca\(^{2+}\) kinetics, contractility, and arrhythmic potential. Validation of respiration analysis was done in a gene-edited HeLa cell line (DNAJC19tv\(_{HeLa}\)).
Results
Structural analyses revealed mitochondrial fragmentation and abnormal cristae formation associated with an overall reduced mitochondrial protein expression in mutant iPSC-CMs. Morphological alterations were associated with higher oxygen consumption rates (OCRs) in all three mutant iPSC-CMs, indicating higher electron transport chain activity to meet cellular ATP demands. Additionally, increased extracellular acidification rates suggested an increase in overall metabolic flux, while radioactive tracer uptake studies revealed decreased fatty acid uptake and utilization of glucose. Mutant iPSC-CMs also showed increased reactive oxygen species (ROS) and an elevated mitochondrial membrane potential. Increased mitochondrial respiration with pyruvate and malate as substrates was observed in mutant DNAJC19tv HeLa cells in addition to an upregulation of respiratory chain complexes, while cellular ATP-levels remain the same. Moreover, mitochondrial alterations were associated with increased beating frequencies, elevated diastolic Ca\(^{2+}\) concentrations, reduced sarcomere shortening and an increased beat-to-beat rate variability in mutant cell lines in response to β-adrenergic stimulation.
Conclusions
Loss of the DnaJ domain disturbs cardiac mitochondrial structure with abnormal cristae formation and leads to mitochondrial dysfunction, suggesting that DNAJC19 plays an essential role in mitochondrial morphogenesis and biogenesis. Moreover, increased mitochondrial respiration, altered substrate utilization, increased ROS production and abnormal Ca\(^{2+}\) kinetics provide insights into the pathogenesis of DCMA-related cardiomyopathy.
Vitamin B6 deficiency has been linked to cognitive impairment in human brain disorders for decades. Still, the molecular mechanisms linking vitamin B6 to these pathologies remain poorly understood, and whether vitamin B6 supplementation improves cognition is unclear as well. Pyridoxal phosphatase (PDXP), an enzyme that controls levels of pyridoxal 5’-phosphate (PLP), the co-enzymatically active form of vitamin B6, may represent an alternative therapeutic entry point into vitamin B6-associated pathologies. However, pharmacological PDXP inhibitors to test this concept are lacking. We now identify a PDXP and age-dependent decline of PLP levels in the murine hippocampus that provides a rationale for the development of PDXP inhibitors. Using a combination of small molecule screening, protein crystallography and biolayer interferometry, we discover and analyze 7,8-dihydroxyflavone (7,8-DHF) as a direct and potent PDXP inhibitor. 7,8-DHF binds and reversibly inhibits PDXP with low micromolar affinity and sub-micromolar potency. In mouse hippocampal neurons, 7,8-DHF increases PLP in a PDXP-dependent manner. These findings validate PDXP as a druggable target. Of note, 7,8-DHF is a well-studied molecule in brain disorder models, although its mechanism of action is actively debated. Our discovery of 7,8-DHF as a PDXP inhibitor offers novel mechanistic insights into the controversy surrounding 7,8-DHF-mediated effects in the brain.
The receptor activity-modifying proteins (RAMPs) are ubiquitously expressed membrane proteins that interact with several G protein-coupled receptors (GPCRs), the largest and pharmacologically most important family of cell surface receptors. RAMPs can regulate GPCR function in terms of ligand-binding, G-protein coupling, downstream signaling, trafficking, and recycling. The integrity of their interactions translates to many physiological functions or pathological conditions.
Regardless of numerous reports on its essential importance for cell biology and pivotal role in (patho-)physiology, the molecular mechanism of how RAMPs modulate GPCR activation remained largely elusive.
This work presents new insights that add to the common understanding of the allosteric regulation of receptor activation and will help interpret how accessory proteins - RAMPs - modulate activation dynamics and how this affects the fundamental aspects of cellular signaling. Using a prototypical class B GPCR, the parathyroid hormone 1 receptor (PTH1R) in the form of advanced genetically encoded optical biosensors, I examined RAMP's impact on the PTH1R activation and signaling in intact cells. A panel of single-cell FRET and confocal microscopy experiments as well canonical and non-canonical functional assays were performed to get a holistic picture of the signaling initiation and transduction of that clinically and therapeutically relevant GPCR. Finally, structural modeling was performed to add molecular mechanistic details to that novel art of modulation.
I describe here that RAMP2 acts as a specific allosteric modulator of PTH1R, shifting PTH1R to a unique pre-activated state that permits faster activation in a ligand-specific manner. Moreover, RAMP2 modulates PTH1R downstream signaling in an agonist-dependent manner, most notably increasing the PTH-mediated Gi3 signaling sensitivity and kinetics of cAMP accumulation. Additionally, RAMP2 increases PTH- and PTHrP-triggered β-arrestin2 recruitment to PTH1R and modulates cytosolic ERK1/2 phosphorylation. Structural homology modeling shows that structural motifs governing GPCR-RAMP interaction originate in allosteric hotspots and rationalize functional modulation. Moreover, to interpret the broader role of RAMP's modulation in GPCRs pharmacology, different fluorescent tools to investigate RAMP's spatial organization were developed, and novel conformational biosensors for class B GPCRs were engineered. Lastly, a high throughput assay is proposed and prototyped to expand the repertoire of RAMPs or other membrane protein interactors.
These data uncover the critical role of RAMPs in GPCR activation and signaling and set up a novel platform for studying GPCR modulation. Furthermore, these insights may provide a new venue for precise modulation of GPCR
function and advanced drug design.
Changes in sugar composition occur continuously in plant tissues at different developmental stages. Tuber dormancy induction, stability, and breaking are very critical developmental transitions in yam crop production. Prolonged tuber dormancy after physiological maturity has constituted a great challenge in yam genetic improvement and productivity. In the present study, biochemical profiling of non-structural sugar in yam tubers during dormancy was performed to determine the role of non-structural sugar in yam tuber dormancy regulation. Two genotypes of the white yam species, one local genotype (Obiaoturugo) and one improved genotype (TDr1100873), were used for this study. Tubers were sampled at 42, 56, 87, 101, 115, and 143 days after physiological maturity (DAPM). Obiaoturugo exhibited a short dormant phenotype and sprouted at 101-DAPM, whereas TDr1100873 exhibited a long dormant phenotype and sprouted at 143-DAPM. Significant metabolic changes were observed in non-structural sugar parameters, dry matter, and moisture content in Obiaoturugo from 56-DAPM, whereas in TDr1100873, significant metabolic changes were observed from 101-DAPM. It was observed that the onset of these metabolic changes occurred at a point when the tubers of both genotypes exhibited a dry matter content of 60%, indicating that a dry matter content of 60% might be a critical threshold for white yam tuber sprouting. Non-reducing sugars increased by 9–10-fold during sprouting in both genotypes, which indicates their key role in tuber dormancy regulation in white yam. This result implicates that some key sugar metabolites can be targeted for dormancy manipulation of the yam crop.
Pyrrolizidine alkaloids (PAs) are secondary plant metabolites, which can be found as contaminant in various foods and herbal products. Several PAs can cause hepatotoxicity and liver cancer via damaging hepatic sinusoidal endothelial cells (HSECs) after hepatic metabolization. HSECs themselves do not express the required metabolic enzymes for activation of PAs. Here we applied a co-culture model to mimic the in vivo hepatic environment and to study PA-induced effects on not metabolically active neighbour cells. In this co-culture model, bioactivation of PA was enabled by metabolically capable human hepatoma cells HepG2, which excrete the toxic and mutagenic pyrrole metabolites. The human cervical epithelial HeLa cells tagged with H2B-GFP were utilized as non-metabolically active neighbours because they can be identified easily based on their green fluorescence in the co-culture. The PAs europine, riddelliine and lasiocarpine induced micronuclei in HepG2 cells, and in HeLa H2B-GFP cells co-cultured with HepG2 cells, but not in HeLa H2B-GFP cells cultured alone. Metabolic inhibition of cytochrome P450 enzymes with ketoconazole abrogated micronucleus formation. The efflux transporter inhibitors verapamil and benzbromarone reduced micronucleus formation in the co-culture model. Furthermore, mitotic disturbances as an additional genotoxic mechanism of action were observed in HepG2 cells and in HeLa H2B-GFP cells co-cultured with HepG2 cells, but not in HeLa H2B-GFP cells cultured alone. Overall, we were able to show that PAs were activated by HepG2 cells and the metabolites induced genomic damage in co-cultured HeLa cells.
Complement 1q/tumor necrosis factor-related proteins (CTRPs): structure, receptors and signaling
(2023)
Adiponectin and the other 15 members of the complement 1q (C1q)/tumor necrosis factor (TNF)-related protein (CTRP) family are secreted proteins composed of an N-terminal variable domain followed by a stalk region and a characteristic C-terminal trimerizing globular C1q (gC1q) domain originally identified in the subunits of the complement protein C1q. We performed a basic PubMed literature search for articles mentioning the various CTRPs or their receptors in the abstract or title. In this narrative review, we briefly summarize the biology of CTRPs and focus then on the structure, receptors and major signaling pathways of CTRPs. Analyses of CTRP knockout mice and CTRP transgenic mice gave overwhelming evidence for the relevance of the anti-inflammatory and insulin-sensitizing effects of CTRPs in autoimmune diseases, obesity, atherosclerosis and cardiac dysfunction. CTRPs form homo- and heterotypic trimers and oligomers which can have different activities. The receptors of some CTRPs are unknown and some receptors are redundantly targeted by several CTRPs. The way in which CTRPs activate their receptors to trigger downstream signaling pathways is largely unknown. CTRPs and their receptors are considered as promising therapeutic targets but their translational usage is still hampered by the limited knowledge of CTRP redundancy and CTRP signal transduction.
Mutations in the mitochondrial-DNA or mitochondria related nuclear-encoded-DNA lead to various multisystemic disorders collectively termed mitochondrial diseases. One in three cases of mitochondrial disease affects the heart muscle, which is called mitochondrial cardiomyopathy (MCM) and is associated with hypertrophic, dilated, and noncompact cardiomyopathy. The heart is an organ with high energy demand, and mitochondria occupy 30%–40% of its cardiomyocyte-cell volume. Mitochondrial dysfunction leads to energy depletion and has detrimental effects on cardiac performance. However, disease development and progression in the context of mitochondrial and nuclear DNA mutations, remains incompletely understood. The system of induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CM) is an excellent platform to study MCM since the unique genetic identity to their donors enables a robust recapitulation of the predicted phenotypes in a dish on a patient-specific level. Here, we focus on recent insights into MCM studied by patient-specific iPSC-CM and further discuss research gaps and advances in metabolic maturation of iPSC-CM, which is crucial for the study of mitochondrial dysfunction and to develop novel therapeutic strategies.
The US National Research Council (NRC) report "Toxicity Testing in the 21st Century: A Vision and a strategy (Tox21)", published in 2007, calls for a complete paradigm shift in tox-icity testing. A central aspect of the proposed strategy includes the transition from apical end-points in in vivo studies to more mechanistically based in vitro tests. To support and facilitate the transition and paradigm shift in toxicity testing, the Adverse Outcome Pathway (AOP) concept is widely recognized as a pragmatic tool. As case studies, the AOP concept was ap-plied in this work to develop AOPs for proximal tubule injuries initiated by Receptor-mediated endocytosis and lysosomal overload and Inhibition of mtDNA polymerase-. These AOPs were used as a mechanistic basis for the development of in vitro assays for each key event (KE). To experimentally support the developed in vitro assays, proximal tubule cells from rat (NRK-52E) and human (RPTEC/TERT1) were treated with model compounds. To measure the dis-turbance of lysosomal function in the AOP – Receptor-mediated endocytosis and lysosomal overload, polymyxin antibiotics (polymyxin B, colistin, polymyxin B nonapeptide) were used as model compounds. Altered expression of lysosomal associated membrane protein 1/2 (LAMP-1/2) (KE1) and cathepsin D release from lysosomes (KE2) were determined by im-munofluorescence, while cytotoxicity (KE3) was measured using the CellTiter-Glo® cell via-bility assay. Importantly, significant differences in polymyxin uptake and susceptibility be-tween cell lines were observed, underlining the importance of in vitro biokinetics to determine an appropriate in vitro point of departure (PoD) for risk assessment. Compared to the in vivo situation, distinct expression of relevant transporters such as megalin and cubilin on mRNA and protein level in the used cell lines (RPTEC/TERT1 and NRK-52E) could not be con-firmed, making integration of quantitative in vitro to in vivo extrapolations (QIVIVE) neces-sary. Integration of QIVIVE by project partners of the University of Utrecht showed an im-provement in the modelled biokinetic data for polymyxin B. To assess the first key event, (KE1) Depletion of mitochondrial DNA, in the AOP – Inhibition of mtDNA polymerase-, a RT-qPCR method was used to determine the mtDNA copy number in cells treated with mod-el compounds (adefovir, cidofovir, tenofovir, adefovir dipivoxil, tenofovir disoproxil fumarate). Mitochondrial toxicity (KE2) was measured by project partners using the high-content imaging technique and MitoTracker® whereas cytotoxicity (KE3) was determined by CellTiter-Glo® cell viability assay. In contrast to the mechanistic hypothesis underlying the AOP – Inhibition of mtDNA polymerase-, treatment with model compounds for 24 h resulted in an increase rather than a decrease in mtDNA copy number (KE1). Only minor effects on mitochondrial toxicity (KE2) and cytotoxicity (KE3) were observed. Treatment of RPT-EC/TERT1 cells for 14 days showed only a slight decrease in mtDNA copy number after treatment with adefovir dipivoxil and tenofovir disoproxil fumarate, underscoring some of the limitations of short-term in vitro systems. To obtain a first estimation for risk assessment based on in vitro data, potential points of departure (PoD) for each KE were calculated from the obtained in vitro data. The most common PoDs were calculated such as the effect concentra-tion at which 10 % or 20_% effect was measured (EC10, EC20), the highest no observed effect concentration (NOEC), the lowest observed effect concentration (LOEC), the benchmark 10 % (lower / upper) concentrations (BMC10, BMCL10, BMCU10) and a modelled non-toxic con-centration (NtC). These PoDs were then compared with serum and tissue concentrations de-termined from in vivo studies after treatment with therapeutic / supratherapeutic doses of the respective drugs in order to obtain a first estimate of risk based on in vitro data. In addition, AOPs were used to test whether the quantitative key event relationships between key events allow prediction of downstream effects and effects on the adverse outcome (AO) based on measurements of an early key event. Predictions of cytotoxicity from the mathematical rela-tionships showed good concordance with measured cytotoxicity after treatment with colistin and polymyxin b nonapeptide. The work also revealed uncertainties and limitations of the ap-plied strategy, which have a significant impact on the prediction and on a risk assessment based on in vitro results.
Targeting the intrinsic metabolism of immune or tumor cells is a therapeutic strategy in autoimmunity, chronic inflammation or cancer. Metabolite repair enzymes may represent an alternative target class for selective metabolic inhibition, but pharmacological tools to test this concept are needed. Here, we demonstrate that phosphoglycolate phosphatase (PGP), a prototypical metabolite repair enzyme in glycolysis, is a pharmacologically actionable target. Using a combination of small molecule screening, protein crystallography, molecular dynamics simulations and NMR metabolomics, we discover and analyze a compound (CP1) that inhibits PGP with high selectivity and submicromolar potency. CP1 locks the phosphatase in a catalytically inactive conformation, dampens glycolytic flux, and phenocopies effects of cellular PGP-deficiency. This study provides key insights into effective and precise PGP targeting, at the same time validating an allosteric approach to control glycolysis that could advance discoveries of innovative therapeutic candidates.